Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Javier Garcia-Corbacho"'
Autor:
Carlos A. Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Juanita Suzanne Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Hyun Cheol Cheol Chung
Publikováno v:
Journal of Clinical Oncology. 39:3564-3564
3564 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient colorectal cancer, both as firs
Autor:
H. Oliveres, Nuria Viñolas, Lydia Gaba, Francis Esposito, Laura Angelats, Estela Pineda, Miquel Nogue, Iván Victoria, Neus Basté Rotllán, Begoña Mellado, Maria Vidal, Olga Martinez Saez, T. Sauri, Laura Ferrer-Mileo, Pol Sole i Bentz, Alberto Indacochea, Javier Garcia-Corbacho, Debora Moreno Fernandez, Montserrat Muñoz, Francisco Pelegrín
Publikováno v:
Journal of Clinical Oncology. 39:3060-3060
3060 Background: Genetic profiling (GP) is essential not only for understanding tumor biology but also helps to identify potential genes for targeted therapies. At the same time, selected CT provide an individual genomic profile panel during the pre-
Autor:
Luis Villanueva, Zarnie Lwin, Hyun Cheol Cheol Chung, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Andrew Eugene Hendifar, Corinne Maurice-Dror, Sanjeev Singh Gill, Tae Won Kim, Daniel Heudobler, Nicolas Penel, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Donna M. Graham
Publikováno v:
Journal of Clinical Oncology. 39:4080-4080
4080 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination with the programmed death-1 immune checkpoint inhibitor pembrolizumab, has
Autor:
Olaf Witt, Toshihiko Doi, Martin Schuler, Gopa Iyer, Christophe Massard, Shonda M Little, Ademi E. Santiago-Walker, Qi Xia, Shubham Pant, Christine Lu-Emerson, Hussein Sweiti, Shukui Qin, Christopher Moy, Javier Garcia-Corbacho, C. Hammond, Darren Hargrave, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 39:TPS480-TPS480
TPS480 Background: The pan- FGFR tyrosine kinase inhibitor erdafitinib is approved by the US Food and Drug Administration for adults with locally advanced or metastatic urothelial carcinoma and susceptible FGFR3/2 genetic alterations who have progres
Autor:
Sanjeev Gill, Kevin Norwood, Donna M. Graham, Andrew Eugene Hendifar, Nicolas Penel, Peter Kubiak, Mark Doherty, Carlos Gomez-Roca, Daniel Heudobler, Zarnie Lwin, Tae Won Kim, Eduardo Yanez, Hélène Senellart, Federico Longo, Javier Garcia-Corbacho, Luis Villanueva, Corinne Maurice-Dror, Hyun Cheol Chung, Fan Jin, Razi Ghori
Publikováno v:
Journal of Clinical Oncology. 39:321-321
321 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination with the programmed death-1 immune checkpoint inhibitor pembrolizumab, has d
Autor:
Javier Garcia-Corbacho, R. Bernabé, Christian Brander, Niki Karachaliou, Rafael Rosell, Andreas Meyerhans, Oscar Juan, Judith Dalmau, Bonaventura Clotet, Julia Garcia-Prado, Mariano Provencio, Javier Martinez-Picado, Javier de Castro, Bartomeu Massuti, Maria Gonzalez-Cao, Julià Blanco, Miguel Angel Molina Vila, Jorge Carrillo, Remei Blanco, Teresa Moran
Publikováno v:
Journal of Clinical Oncology. 37:2501-2501
2501 Background: Durvalumab (MEDI4736), a programmed cell death-ligand 1 (PD-L1) blocking antibody, is currently approved for treatment of several cancer types. As HIV-1-infected (HIV+) patients have been excluded from cancer clinical trials, there a
Autor:
Hendrik-Tobias Arkenau, Vanessa Huels, Fiona C Thistlethwaite, Nataliya Volodymyrivna Uboha, Bert H. O'Neil, Beverly A. Benson, William J. Garner, Omid Hamid, Javier Garcia-Corbacho, Javier Lavernia, Ferry A.L.M. Eskens, Manreet Randhawa, Anthony B. El-Khoueiry, Aung Naing, Patricia LoRusso, Alexander I. Spira
Publikováno v:
Journal of Clinical Oncology. 37:2513-2513
2513 Background: Anti-programmed cell death ligand 1 (PD-L1) immunotherapies have improved survival in many cancers, but immune-related adverse events (irAEs) have been observed, especially in combination therapy. CX-072 is an investigational Probody
Autor:
Hans Wildiers, Martine Piccart-Gebhart, Manuel Ruiz Borrego, Valentina Boni, Nicolas Isambert, Cecilia Simonelli, Begona Jimenez-Rodriguez, Philippe Aftimos, Andrea Pellacani, Cristina Saura, Diego Tosi, Bernard Doger, Andrew M Wardley, François Duhoux, Hendrik-Tobias Arkenau, Iñaki F. Trocóniz, Andrea Varga, Monica Binaschi, Javier Garcia Corbacho, Mario Campone
Publikováno v:
Journal of Clinical Oncology. 37:TPS1101-TPS1101
TPS1101 Background: MEN1611 is a potent, selective class I inhibitor of PI3K, a key enzyme in the transduction of various extracellular growth factor signals essential for cell survival and apoptosis. The discovery in human cancers of frequent PIK3CA
Autor:
Simon Pacey, Paul M. Loadman, Gareth Griffiths, Alison Young, Margaret A. Knowles, Tracie-Ann Madden, Alison Birtle, Mirela Hategan, John D. Chester, Robert Jones, Sanjeev Kumar, Richard Adams, Angela C. Casbard, Javier Garcia Corbacho, Andrew Protheroe
Background: gemcitabine (G) and cisplatin (C) is a standard-of-care, combination chemotherapy regimen for neoadjuvant treatment of muscle-invasive and palliative treatment of advanced bladder cancer (BC). More effective regimens are urgently needed,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38fcb7ea53c7acc828f1f3cbdfe7283
https://www.repository.cam.ac.uk/handle/1810/286033
https://www.repository.cam.ac.uk/handle/1810/286033
Autor:
Mirela Hategan, Andrea Machin, Wanfeng Zhao, Nimish Shah, Sanjeev Srinivas Kumar, Wendi Qian, Barry R. Davies, Anne Y. Warren, Javier Garcia Corbacho, Susan Ingle, Simon Pacey, Elizabeth A. Harrington, Richard D. Baird, Ola Bratt, Elisabeth Oelmann, Sara Stearn, Vincent Gnanapragasam
Publikováno v:
Journal of Clinical Oncology. 36:5081-5081
5081Background: The effect of novel drugs can be studied in primary prostate cancer (PC), if given prior to radical prostatectomy (RP). Altered PI3K/AKT/mTOR signalling is associated with aggressiv...